Compare Occidental Petroleum Corporation (OXY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Sanofi SA — how do they compare? Occidental Petroleum Corporation trades at $57.62 (market cap $56.20B), while Sanofi SA trades at $44.12 (market cap $104.85B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| OXY | SNY | |
|---|---|---|
Market Cap | $56.20B | $104.85B |
Sector | Energy | Health |
52-Week High | $66.24 | $52.34 |
52-Week Low | $38.92 | $41.33 |
Enterprise Value | $77.28B | $121.38B |
Dividend Yield | 1.84% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $56.50, up 2.99% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 22.42% net income margin and robust cash flow from operations of $10.53B in 2025. Recent news highlights Permian Basin growth and capital spending cuts, while analyst consensus leans bullish with a $65.38 price target.
OXY presents upside potential driven by earnings momentum and debt reduction, but faces risks from oil price volatility and declining revenue trends. The stock's elevated P/E ratio of 74.58 warrants caution, though institutional support and strategic positioning in carbon capture technology offer long-term value. Current levels near resistance at $57 require monitoring for breakout confirmation.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
